UROGESIC-BLUE – prescribing information (methenamine, monobasic sodium phosphate, methylene blue, hyoscyamine sulfate), Edwards Pharmaceuticals (2026)

Government Record · Edwards Pharmaceuticals, Inc. (labeler) · November 17, 2026

Edwards Pharmaceuticals et al., 2026-11-17: Urogesic-Blue (Edwards Pharmaceuticals, NDC 0485-0151-30 and -01) is a current urinary combination tablet with 10.8 mg methylene blue, methenamine 81.6 mg, monobasic sodium phosphate 40.8 mg and hyoscyamine sulfate 0.12 mg; like Uribel its SPL shows no application number.

UROGESIC-BLUE™ is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic.

Edwards Pharmaceuticals et al., 2026-11-17: Urogesic-Blue (Edwards Pharmaceuticals, NDC 0485-0151-30 and -01) is a current urinary combination tablet with 10.8 mg methylene blue, methenamine 81.6 mg, monobasic sodium phosphate 40.8 mg and hyoscyamine sulfate 0.12 mg; like Uribel its SPL shows no application number. C8 – urinary combination product, current status. Two SPLs are live for the same product: set id d820e42d (bottles of 30, DailyMed SPL version 5 published 2026-11-17; label Updated date 2026-11-15) and f650dd78-615c-42d3-9b2d-3a989039d80c (bottles of 100, effective 2026-11-11). openFDA application_number field empty for both. Marketed as Rx only. Related labels in the same openFDA result set: Urelle (Viatris Specialty LLC, set id 1d80a11c, label effective 2015-01-13), Uro-MP (Method Pharmaceuticals, effective 2025-10-29), Urimar-T (Allegis), Uretron D/S (Doral), MB Caps (Allegis) – all methylene-blue-containing urinary combinations with no application number in their SPL metadata. Fetch route: openFDA drug/label by set_id. Study type: regulatory record.